KRT16 antibody (C-Term)

Catalog No. ABIN7877411

This Mouse Monoclonal antibody specifically detects KRT16 in IHC (p). It exhibits reactivity toward Human.

Quick Overview for KRT16 antibody (C-Term) (ABIN7877411)

Target: KRT16 (Keratin 16 (KRT16))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This KRT16 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: SPM264

Product Details anti-KRT16 Antibody

Binding Specificity: C-Term

Purpose: KRT16 Antibody / Cytokeratin 16 (azide and preservative free)

Purification: Protein A/G affinity

Immunogen: A recombinant protein fragment from the C-terminal region was used as the immunogen for the KRT16 antibody.

Isotype: IgG1, kappa

Application Details

Application Notes: Optimal dilution of the KRT16 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: -20 °C

Storage Comment: Aliquot the KRT16 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for KRT16

Target: KRT16 (Keratin 16 (KRT16))

Alternative Name: KRT16

Background: Cytokeratins are a family of intermediate filament proteins that assemble into filaments through forming heterodimers of one type I Cytokeratins (Cytokeratins 9 to 23) and one type II Cytokeratins (keratins 1 to 8). The cytokeratin proteins play a critical role in differentiation, as well as tissue specialization and function, to maintain the overall structural integrity of epithelial cells. Cytokeratins are also useful markers in identifying the origin of metastatic tumors. Cytokeratin 16 is expressed in benign stratified squamous epithelium and squamous cell carcinoma of the head and neck, as well as luminal cells of mammary gland and sweat ducts. It is absent in non-invasive breast carcinomas and normal breast tissue.

UniProt: P08779